Amneal Pharmaceuticals Inc. has named former Apotex vice-president of global R&D, Pradeep Bhadauria, as Amneal’s chief scientific officer with immediate effect, succeeding current CSO Shankar Hariharan who will leave the company on 24 May. Citing Bhadauria’s “significant R&D expertise” – with over 20 years of experience leading development for generics and specialty pharmaceutical firms including Actavis – Amneal said he had overseen the development and filing of more than 200 products, “including numerous first-to-file and first-to-market opportunities”. In particular, noted Amneal’s president and CEO, Rob Stewart, Bhadauria had “demonstrated strength in developing complex generics and other difficult-to-formulate products”, which would be “a strong asset to our company as we continue to diversify our pipeline and portfolio”.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?